<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1098">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581746</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH_2020_7</org_study_id>
    <nct_id>NCT04581746</nct_id>
  </id_info>
  <brief_title>Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)</brief_title>
  <acronym>coVIHd-19</acronym>
  <official_title>Evaluation of the Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The non-essential and non-urgent follow-up consultations of patients living with HIV were&#xD;
      postponed or transformed into &quot;teleconsultation&quot; or exchanges of e-mails between&#xD;
      practitioners and patients during COVID-19 epidemic. This change in care can have an impact&#xD;
      on follow-up and access to treatment for PVVIH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On 16 March 2020, an instruction to postpone &quot;non-urgent&quot; consultations was given to doctors.&#xD;
      Thus, the non-essential and non-urgent follow-up consultations of patients living with HIV&#xD;
      were postponed or transformed into &quot;teleconsultation&quot; or exchanges of e-mails between&#xD;
      practitioners and patients. This change in care can have an impact on follow-up and access to&#xD;
      treatment for PVVIH. In addition, the epidemic itself may have consequences: PVVIH may be at&#xD;
      greater risk because of their immunosuppression and associated co-morbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of SARS CoV2 infection in PVVIH in Hauts de France</measure>
    <time_frame>Inclusion</time_frame>
    <description>Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at inclusion in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of SARS CoV2 infection in PVVIH in Hauts de France</measure>
    <time_frame>through study completion, an average of 19 months</time_frame>
    <description>Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment</measure>
    <time_frame>through study completion, an average of 19 months</time_frame>
    <description>Percentage of patients who stopped their antiretroviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment</measure>
    <time_frame>through study completion, an average of 19 months</time_frame>
    <description>Reason for discontinuing antiretroviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up</measure>
    <time_frame>through study completion, an average of 19 months</time_frame>
    <description>Percentage of patients who stopped all follow-up by an infectious disease specialist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological consequences of this epidemic among PVVIH : HAD</measure>
    <time_frame>through study completion, an average of 19 months</time_frame>
    <description>Evaluation of the psychological scales HAD on PVVIH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological consequences of this epidemic among PVVIH : PROQOL-HIV</measure>
    <time_frame>through study completion, an average of 19 months</time_frame>
    <description>Evaluation of the psychological scales PROQOL-HIV on PVVIH</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Virus-HIV</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>questionnaire and follow-up visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>bi-monthly questionnaire and then one visit with questionnaire and covid-19 test</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient followed up for HIV infection in one of the COREVIH Hauts de France centres&#xD;
             participating in the study&#xD;
&#xD;
          -  Having communicated an email address&#xD;
&#xD;
          -  Having given their consent to participate in this study&#xD;
&#xD;
          -  Beneficiary subject affiliated or entitled to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor patient&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline THILL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline THILL, MD</last_name>
    <phone>0320694949</phone>
    <email>pthill@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solange TREHOUX, PhD</last_name>
    <phone>0320694280</phone>
    <email>strehoux@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

